Filed with the United States Patent and Trademark Office (USPTO), the U.S. patent application number US 7,674,456 B2, Priority Date: June 14, 2004, includes the following:
- Compositions and cell lines
- Therapeutic methods of using compositions of SV-BR Cells
BriaCell™ has obtained the exclusive license to its patent application from St. Vincent’s Medical Center, and the resulting patent will have a term extending to 2024. Hatch-Waxman extension potentially applies (additional five years).
On March 7, 2017, BriaCell™ filed an international patent application under the Patent Cooperation Treaty (PCT) to further expand its intellectual property portfolio underlying the Company’s current and anticipated pipeline of whole-cell cancer immunotherapeutics including Bria-IMT™ and Bria-OTS™. The PCT application (PCT/US2017/019757) includes the scope of two provisional patent applications filed by the Company with the United States Patent and Trademark Office (USPTO) in 2016. It, in essence, provides the framework for additional whole-cell cancer immunotherapeutics beyond Bria-IMT™ and strategies for patient-specific selection of the most likely most effective whole-cell immunotherapeutic (BriaDx™). The PCT patent application entered the National Phase in the second half of 2018.
Small Molecule Program
On Nov 13, 2017, BriaCell™ disclosed the allowance by the US Patent and Trademark Office (USPTO) and also the European Patent Office (EPO) of two patent applications related to protein kinase C delta (PKCδ) inhibitor technology, titled “PKC Delta Inhibitors for use as Therapeutics”.
Additional patent applications are expected to be filed in 2020.